| BCLI |
Brainstorm Cell Therapeutics Inc. |
72%
|
Reciprocal relationship from BCLI graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from BCLI graph: Reciprocal relationship from NSRX graph: for the foreseeable future, and we … |
| BCLI |
Brainstorm Cell Therapeutics Inc. |
72%
|
for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining ne… |
| ADAPT-PHARMA-INC-TEVA-PHARMACEUTICALS-LTD-PFIZER |
ADAPT-PHARMA-INC-TEVA-PHARMACEUTICALS-LTD-PFIZER |
62%
|
cluding use restrictions contained in the product’s approved labeling; ● distribution and use restrictions imposed by the EMA, FDA or other regulatory authority or agreed to by us as part of a mandat… |
| APTAR-GROUP-INC |
APTAR-GROUP-INC |
62%
|
tion of investigations by regulators or other authorities; and ● the inability to successfully commercialize our product candidates, if approved. 24 Further, our business exposes us to an inherent ri… |
| ATOX-BIO-LTD |
ATOX-BIO-LTD |
62%
|
for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining ne… |
| BUSINESS-NASUS-PHARMA-LTD |
BUSINESS-NASUS-PHARMA-LTD |
62%
|
NOTE 1: ORGANIZATION AND NATURE OF THE BUSINESS a. Description of the Business Nasus Pharma Ltd. (the “Company”) was incorporated in May 2019 under the laws of the State of Israel. The Company is a c… |
| CAPITAL-POINT-LTD |
CAPITAL-POINT-LTD |
62%
|
ices agreement has an initial term of 36 months from the effective date. We may terminate the agreement or any statement of work for convenience upon 30 days’ prior written notice, and either party m… |
| FORMULEX-PHARMA-INNOVATIONS-LTD |
FORMULEX-PHARMA-INNOVATIONS-LTD |
62%
|
bservations. F- 16 NASUS PHARMA LTD. AND ITS SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Amounts in thousands, except share and per share amounts) NOTE 6:- CONTINGENT LIABILITIES AND COMMI… |
| HERSHMAN-HOLDINGS-LLC |
HERSHMAN-HOLDINGS-LLC |
62%
|
ices agreement has an initial term of 36 months from the effective date. We may terminate the agreement or any statement of work for convenience upon 30 days’ prior written notice, and either party m… |
| NASUS-PHARMA-UK-LTD |
NASUS-PHARMA-UK-LTD |
62%
|
udulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim incl… |
| NYSE-AMERICAN-LLC-COMPANY |
NYSE-AMERICAN-LLC-COMPANY |
62%
|
for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining ne… |
| PAINREFORM-LTD |
PAINREFORM-LTD |
62%
|
for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining ne… |
| PLX |
Protalix BioTherapeutics, Inc. |
62%
|
Reciprocal relationship from PLX graph: Reciprocal relationship from NSRX graph: for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about … |
| PROTALIX-BIOTHERAPEUTICS-INC |
PROTALIX-BIOTHERAPEUTICS-INC |
62%
|
for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining ne… |
| TAMARIX-PHARMA-LTD |
TAMARIX-PHARMA-LTD |
62%
|
for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining ne… |
